SVRA - Savara Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
3.3400
-0.1500 (-4.30%)
At close: 4:00PM EST
Stock chart is not supported by your current browser
Previous Close3.4900
Open3.4500
Bid2.7400 x 1000
Ask0.0000 x 1100
Day's Range3.2500 - 3.4760
52 Week Range0.6900 - 11.9600
Volume335,665
Avg. Volume1,747,438
Market Cap137.643M
Beta (5Y Monthly)1.56
PE Ratio (TTM)N/A
EPS (TTM)-1.4970
Earnings DateNov 06, 2019
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est5.44
  • Is Savara Inc. (NASDAQ:SVRA) A Volatile Stock?
    Simply Wall St.

    Is Savara Inc. (NASDAQ:SVRA) A Volatile Stock?

    Anyone researching Savara Inc. (NASDAQ:SVRA) might want to consider the historical volatility of the share price...

  • In the money Jan. 6: Drug, burger makers report multimillion-dollar fundings
    American City Business Journals

    In the money Jan. 6: Drug, burger makers report multimillion-dollar fundings

    A LLC for P. Terry's Burger Stand and a publicly traded pharmaceutical company are among those reporting new money. This list is often a gold mine for job seekers, salespeople and executives trying to keep tabs on the competition.

  • Are Options Traders Betting on a Big Move in Savara (SVRA) Stock?
    Zacks

    Are Options Traders Betting on a Big Move in Savara (SVRA) Stock?

    Investors need to pay close attention to Savara (SVRA) stock based on the movements in the options market lately.

  • Business Wire

    Savara Granted Breakthrough Therapy Designation for Molgradex for the Treatment of Autoimmune Pulmonary Alveolar Proteinosis (aPAP)

    Savara Inc. (Nasdaq: SVRA), an orphan lung disease company, today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy designation for Molgradex, an inhaled formulation of recombinant human granulocyte-macrophage colony-stimulating factor (GM-CSF), for the treatment of aPAP.

  • Business Wire

    Savara Announces Private Placement of $26.8 Million, With Total Potential Proceeds of $75.0 Million

    Savara Inc. (Nasdaq: SVRA), an orphan lung disease company, today announced that it has entered into a definitive agreement for a private placement with institutional investors to purchase an aggregate of 9,569,430 shares of common stock and, in lieu of shares of common stock, pre-funded warrants to purchase an aggregate of 5,780,537 shares of common stock, and accompanying warrants (the "Milestone Warrants") to purchase an aggregate of up to 32,577,209 additional shares of common stock (or pre-funded warrants to purchase common stock in lieu thereof) at a price of $1.745 per share and accompanying Milestone Warrant (or $1.744 per pre-funded warrant and accompanying Milestone Warrant). The price per pre-funded warrant and accompanying Milestone Warrant represents the price of $1.745 per share and accompanying Milestone Warrant to be sold in the private placement, minus the $0.001 per share exercise price of each such pre-funded warrant. The exercise price of the Milestone Warrants is $1.48 per share, or if exercised for a pre-funded warrant in lieu thereof, $1.479 per pre-funded warrant (representing the Milestone Warrant exercise price of $1.48 per share minus the $0.001 per share exercise price of each such pre-funded warrant). The Milestone Warrants are exercisable at any time prior to the earlier of 30 days following the achievement of a defined clinical milestone or two years after the closing date of the private placement. The gross proceeds from the sales of common stock and pre-funded warrants are expected to be $26.8 million, before deducting placement agent fees and estimated offering expenses payable by Savara. If the Milestone Warrants are exercised in full, Savara would receive additional gross proceeds of $48.2 million, resulting in total transaction gross proceeds of $75.0 million, in each case before deducting placement agent fees and estimated offering expenses payable by Savara. The private placement, led by Bain Capital Life Sciences, with participation by certain existing and new investors, including EcoR1 Capital LLC and Logos Capital, is expected to close on December 24, 2019, subject to customary closing conditions. In connection with the closing, Ricky Sun, Ph.D. of Bain Capital Life Sciences is expected to join the Savara board of directors.

  • Is Savara, Inc. (SVRA) A Good Stock To Buy?
    Insider Monkey

    Is Savara, Inc. (SVRA) A Good Stock To Buy?

    Like everyone else, elite investors make mistakes. Some of their top consensus picks, such as Amazon, Facebook and Alibaba, have not done well in Q4 of 2018 due to various reasons. Nevertheless, the data show elite investors' consensus picks have done well on average over the long-term. The top 20 stocks among hedge funds beat […]

  • Business Wire

    Savara Announces the Appointment of Dr. An van Es-Johansson to Board of Directors

    Savara Inc. (SVRA), an orphan lung disease company, today announced the appointment of Dr. An van Es-Johansson, M.D. to its Board of Directors, effective immediately. Dr. van Es-Johansson has extensive experience in the development of FDA- and EMA-approved orphan products and has held global leadership roles across multiple disciplines of the life sciences industry, including clinical development, regulatory, and medical affairs.

  • 2 Falling Knives for Investors to Consider
    GuruFocus.com

    2 Falling Knives for Investors to Consider

    These companies have a low financial burden Continue reading...

  • Business Wire

    Savara Announces New Employment Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)

    Savara Inc. (SVRA), an orphan lung disease company, today announced that on November 26, 2019, the independent members of the Company's Board of Directors granted Badrul Chowdhury, M.D., Ph.D., the Company's new Chief Medical Officer, an option to purchase 300,000 shares of the Company's common stock with an exercise price of $1.01 per share, the closing trading price of the Company's common stock on the NASDAQ Global Market on the grant date of November 26, 2019. The option vests as to 1/16th of the number of shares subject to the option each quarter with vesting commencing on November 15, 2019, subject to continued employment on each such vesting date, and the option has a ten-year term.

  • Business Wire

    Savara’s COO and CMO to Present at the Evercore ISI 2nd Annual HealthCONx Conference

    Savara Inc. , an orphan lung disease company, will be presenting at the Evercore ISI HealthCONx conference on Wednesday, December 4, 2019 at 2:20 PM ET / 11:20 AM PT at the Four Seasons Hotel in Boston.

  • Business Wire

    Savara Appoints Badrul Chowdhury, M.D., Ph.D as Chief Medical Officer

    Savara Inc. (SVRA), an orphan lung disease company, today announced the appointment of Badrul Chowdhury, M.D., Ph.D., to the newly created position of Chief Medical Officer (CMO), effective immediately. Dr. Chowdhury will be Savara’s senior physician overseeing the medical and regulatory strategy of the Company’s investigational programs from late-stage development through to approval.

  • ACCESSWIRE

    SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Savara Inc. - SVRA

    NEW YORK, NY / ACCESSWIRE / November 15, 2019 / Pomerantz LLP is investigating claims on behalf of investors of Savara Inc. ("Savara" or the "Company") (NASDAQ:SVRA). Such investors ...

  • GlobeNewswire

    SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Savara Inc. – SVRA

    Pomerantz LLP is investigating claims on behalf of investors of Savara Inc. (“Savara” or the “Company”) (SVRA). Such investors are advised to contact Robert S. Willoughby at rswilloughby@pomlaw.com or 888-476-6529, ext. The investigation concerns whether Savara and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.

  • Business Wire

    Savara to Present at the Stifel 2019 Healthcare Conference

    Savara Inc. , an orphan lung disease company, will be presenting at the Stifel 2019 Healthcare Conference on Tuesday, November 19, 2019 at 3:00 PM ET / 12:00 PM PT at the Lotte New York Palace Hotel.

  • GlobeNewswire

    SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Savara Inc. - SVRA

    Pomerantz LLP is investigating claims on behalf of investors of Savara Inc. (“Savara” or the “Company”) (SVRA). Such investors are advised to contact Robert S. Willoughby at rswilloughby@pomlaw.com or 888-476-6529, ext. The investigation concerns whether Savara and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.

  • Business Wire

    Savara Reports Third Quarter 2019 Financial Results and Provides Business Update

    Company in Discussions with Regulatory Agencies on Best Path Forward for the Molgradex Autoimmune Pulmonary Alveolar Proteinosis Program

  • Business Wire

    Savara to Report Third Quarter 2019 Financial Results and Provide Business Update

    Savara Inc. , an orphan lung disease company, today announced that the Company will report third quarter 2019 financial results and provide a business update on Thursday, November 7, 2019.

  • Have Insiders Been Buying Savara Inc. (NASDAQ:SVRA) Shares?
    Simply Wall St.

    Have Insiders Been Buying Savara Inc. (NASDAQ:SVRA) Shares?

    We often see insiders buying up shares in companies that perform well over the long term. The flip side of that is...

  • ACCESSWIRE

    Bronstein, Gewirtz & Grossman, LLC Announces Investigation of Savara Inc. (SVRA)

    NEW YORK, NY / ACCESSWIRE / October 3, 2019 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Savara Inc. ("Savara" or "the Company") ...

  • Company News For Oct 3, 2019
    Zacks

    Company News For Oct 3, 2019

    Companies in the news are: SVRA, LEN, F, JNJ